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ABSTRACT 
Flaws in trial design may bias intervention effect estimates and increase between-trial heterogeneity. 
Empirical evidence suggests that these problems are greatest for subjectively assessed outcomes. 
For the ROBES study, we extracted risk-of-bias judgements (for sequence generation, allocation 
concealment, blinding and incomplete data) from a large collection of meta-analyses published in the 
Cochrane Library, issue 4, 2011. We categorized outcome measures as mortality, other objective or 
subjective, and estimated associations of bias judgements with intervention effect estimates using 
Bayesian hierarchical models. Among 2443 trials in 228 meta-analyses, intervention effect estimates 
were on average exaggerated in trials with high or unclear risk-of-bias judgements (versus low) for 
sequence generation (ratio of odds ratio 0.91 [95% credible interval 0.86, 0.98]), allocation 
concealment (0.92 [0.86, 0.98]) and blinding (0.87 [0.80, 0.93]). In contrast to previous work, we did 
not observe consistently different bias for subjective outcomes compared with mortality. However, we 
found an increase in between-trial heterogeneity associated with lack of blinding in meta-analyses 
with subjective outcomes. Inconsistency in criteria for risk-of-bias judgments applied by individual 
reviewers is a likely limitation of routinely collected bias assessments. Inadequate randomization and 
lack of blinding may lead to exaggeration of intervention effect estimates in trials. 
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Meta-analyses of randomized trials are often more influential than single trials, and increasingly 
inform healthcare decisions made by clinicians and health authorities. For their results to be valid, 
trials should employ rigorous methods that can achieve and preserve comparability of the intervention 
and control groups.(1) For example, concealment of randomized allocation prevents an influence of 
patient characteristics on allocation to intervention and control groups; blinding of participants and trial 
personnel prevents differences in patient management between groups; and blinding of outcome 
assessors prevents knowledge of the assigned intervention group influencing outcome measurement. 
Randomized trials vary in methodological rigour, and flaws in trial conduct can lead to biased 
estimation of the intervention effect.(2) Systematic reviewers should therefore assess the risk of bias 
in intervention effect estimates from each included trial. 
Meta-epidemiologic studies analyse collections of meta-analyses to provide empirical evidence about 
the influence of trial design characteristics on trial results.(3) Such studies have, however, reached 
differing conclusions about which trial design characteristics most influence their results.(4-8) For 
example, four studies found that lack of adequate allocation concealment was associated with 
overestimation of treatment effect,(9-12) while several other studies did not find evidence for this.(4, 
5, 13-15)  In a previous study we explored reasons for these discrepancies by combining data from 
seven meta-epidemiologic studies.(16, 17) This was the first study to explore the effects of bias on 
between and within meta-analysis heterogeneity using Bayesian hierarchical models. The results 
suggested that trial results based on subjectively assessed outcomes are more susceptible to bias 
and that the effect of bias is unpredictable, leading to increased heterogeneity in meta-analyses 
assessing subjective outcomes. (16, 17) Further investigation of the effects of trial characteristics 
across different interventions, settings and outcomes in larger collections of meta-analyses (not 
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Since January 2008, authors of Cochrane reviews have used a 'Risk of Bias' tool for assessing 
included trials.(18) The assessors make judgments in relation to “sequence generation”, “allocation 
concealment”, “blinding of participants, personnel and outcome assessors”, “incomplete outcome 
data”, “selective outcome reporting”, and a general category of “other potential threats to validity”. For 
each of these areas, review authors record whether there was a judgement of low, high or unclear risk 
of bias for each trial, together with comments or quotes to justify each judgement. Accumulated 
standardized risk-of-bias assessments are a potentially a useful resource for meta-epidemiologic 
research.  
This paper describes and reports the main results from the ROBES study (Risk Of Bias in Evidence 
Synthesis). The ROBES study is a new, large empirical study investigating the associations of risk-of-
bias judgements for sequence generation, allocation concealment, blinding and incomplete outcome 
data with treatment effect estimates. Our aims were to examine whether routinely collected risk of 
bias assessments relating to methodological characteristics are associated with effect estimates, to 
compare these associations with findings from our previous study,(17) and to examine further the 




The April 2011 issue of the Cochrane Database of Systematic Reviews included 4371 intervention 
reviews (excluding protocols), of which 1399 had at least two completed domains in the Risk of Bias 
tables. The complete 1399 reviews were supplied by the Cochrane Informatics & Knowledge 
Management Department in the format of Review Manager (rm5) files.(19) We converted these to a 
customized Microsoft Access database using bespoke software which we commissioned from 
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Data selection and categorization 
We selected meta-analyses that fulfilled the following criteria: (i) address a binary outcome; (ii) include 
at least five trials, each with at least one event across the two trial arms; (iii) accompanied by risk of 
bias assessments, with all five core domains of the tool having been assessed (sequence generation, 
allocation concealment, blinding, incomplete outcome data and selective outcome reporting); (iv) 
compare an active intervention with a control or „older‟ intervention; (v) include no trials that 
overlapped with another meta-analysis in the data set. Details of the process for selecting eligible 
meta-analyses are provided in Web Appendix 1. Meta-analyses can inform estimation of the bias 
associated with a particular domain only if they contain at least one trial at „low risk‟ of bias and one at 
„high or unclear‟ risk of bias. We refer to these as informative meta-analyses for that bias domain.  
We categorized each meta-analysis according to objectivity of the outcome measure (see below); 
direction of outcome (whether adverse or favorable),(16, 17) type of intervention (pharmacological, 
surgical, psychosocial and behavioral, care pathways, and other), clinical area (based on the 
International Classification of Diseases 10th Revision, ICD-10),(20) and whether the comparator was 
an active intervention (i.e. not a placebo, untreated or standard care). Classification of outcome 
measure objectivity followed Savović et al. (16, 17): we categorized outcome measures as (a) all-
cause mortality; (b) other objectively assessed (including live births, non-cephalic births, low 
birthweight, miscarriage, pregnancy and all automated laboratory outcomes); (c) semi-objective 
(where the outcome event is considered to be measured accurately but the decision behind it 
influenced by a clinician‟s or patient‟s judgement, e.g. hospital admissions or re-admissions, total 
dropouts/withdrawals for any reason, treatment completers, caesarean section, spontaneous vaginal 
birth, operative/assisted delivery, conversion to open surgery, additional treatments administered); 
and (d) subjectively assessed (e.g. clinician assessed outcomes, symptoms and symptom scores, 
pain, mental health outcomes, cause-specific mortality). Too few meta-analyses had outcomes in the 
objective and semi-objective categories (b and c) for separate analyses to be possible, so we 
combined these categories as “other objective”. When both objective and subjective methods of 
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analysis was categorized as having a subjectively assessed outcome (e.g. some trials in meta-
analyses examining smoking cessation used a laboratory measure, while others used patient self-
reporting).  
Statistical analysis 
To explore correlations between bias domains, we computed odds ratios for the association between 
risk of bias judgements for pairs of domains using logistic regression in Stata 14. For the main 
analyses, we modelled intervention effects as log odds ratios (ORs) with outcomes coded so that ORs 
less than 1 corresponded to beneficial intervention effects in all meta-analyses. In the main analysis, 
„high risk‟ and „unclear risk‟ bias judgments were grouped together. The underlying idea of the 
analysis is described in Web Appendix 2 and illustrated in Web Figure 1. We fitted Bayesian 
hierarchical bias models, assuming a binomial likelihood („Model 3‟ by Welton et al.(21)). This 
assumes random intervention effects (between-trial heterogeneity) within meta-analyses, which 
allows us to assess whether individual bias domains are associated with increased heterogeneity. 
The model includes parameters for average bias in intervention effects (log odds ratios comparing 
trials at „high or unclear‟ with „low‟ risk of bias, averaged across all meta-analyses) and two sources of 
variation in bias. Variation in bias among trials within meta-analyses was quantified using a term κ2, 
representing the average increase in between-trial heterogeneity in trials at „high or unclear risk‟ of 
bias (vs. „low‟ risk of bias) for each bias domain.  Variation in mean bias across meta-analyses was 
quantified by a between–meta-analysis variance φ2. Posterior means for average bias were 
exponentiated and reported as ratios of odds ratios (RORs); posterior medians for κ and φ are 
reported on the log odds ratio scale; all are presented with 95% credible intervals (CrIs). Meta-
analyses containing fewer than two studies at „low risk‟ of bias and at „high or unclear‟ risk of bias are 
uninformative for κ, and were prevented from influencing the estimation of this parameter. Additional 
statistical analysis information and analysis code is provided in Web Appendix 2. 
We conducted univariable analyses for each of four risk of bias domains (sequence generation, 
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for that domain (Model A in Web Appendix 2). We did not explore the association between the 
selective outcome reporting domain and intervention effect estimates. This domain currently 
addresses the non-reporting of outcomes rather than bias in the results available for meta-analysis, 
so is not directly relevant to bias in the observed results. Analyses were also stratified according to 
type of outcome measure (all-cause mortality, other objectively assessed, and subjectively assessed). 
Multivariable analyses were based on an extended model assuming distinct variance components 
associated with each bias domain (Model B in Web Appendix 2), described in Savović et al.(16) We 
also fitted multivariable analyses that allowed interactions between sequence generation and 
allocation concealment; allocation concealment and blinding; and sequence generation and blinding 
(Model C in Web Appendix 2). We conducted a univariable sensitivity analysis combining trials with 
an „unclear risk‟ of bias judgement with those with „low risk‟ of bias (rather than with „high risk‟). We 
also conducted separate analyses for objective and semi-objective outcomes.  
 
RESULTS 
Following our selection process the final ROBES study dataset consisted of 228 meta-analyses 
containing 2443 trials (Error! Reference source not found.). The full list of included reviews and 
meta-analysis is provided in the Web Appendix 3. The median year of publication of included reviews 
was 2008 (interquartile range 2005 to 2010, range 1996 to 2011), and for trials 1999 (inter-quartile 
range 1992 to 2005, range 1950 to 2011). The median sample size was 1290 (inter-quartile range 
676 to 3403, range 110 to 341,351) for meta-analyses and 114 (interquartile range 60 to 256, range 8 
to 182,000) for trials. Based on the categorization of clinical areas according to World Health 
Organization International Classification of Diseases 10th revision, the most frequently assessed 
conditions were related to pregnancy and childbirth (28 meta-analyses, 12.3 %) and mental health 
(27, 11.8 %), followed by circulatory (21, 9.2 %), and respiratory (20, 8.8 %) system conditions. 
Subjectively assessed outcomes were reported most frequently, in 127 (55.7%) meta-analyses, 
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The proportion of trials judged as at low risk of bias was highest for the incomplete outcome data 
domain (1493 trials, 61.1%), followed by sequence generation (1143, 46.8%), blinding (1119, 45.8%) 
and allocation concealment (1033, 42.3%). The proportion of trials with unclear risk of bias was 
highest for allocation concealment (1267, 51.9%) and sequence generation (1226, 50.2%), and was 
markedly lower for blinding (641, 26.2%) and incomplete outcome data (580, 23.7%). The proportion 
of trials rated as high risk of bias was highest for blinding (683, 28.0%), followed by incomplete 
outcome data (370, 15.2%), with low proportions rated as high risk for allocation concealment (143, 
5.9%), and sequence generation (74, 3.0%) (Table 2). Numbers of trials with each combination of the 
four risk of bias domain judgements by type of outcome are shown in Web Figure 2, Web Appendix 4. 
For sequence generation, 2158 trials were included in 189 (82.9%) informative meta-analyses, of 
which 1006 (46.6%) were judged as low, 1081 (50.1%) unclear, and 71 (3.3%) high risk of bias. For 
allocation concealment, 2121 trials were included in 188 (82.5%) informative meta-analyses, of which 
933 (44.0%) were judged as low, 1068 (50.3%) as unclear and 120 (5.7%) as high risk of bias. Only 
144 (63.2%) meta-analyses (1678 trials) were informative for blinding: 854 (50.9%) trials were judged 
as low, 437 (26.0%) as unclear, and 387 (23.1%) as high risk of bias. For incomplete outcome data, 
1956 trials were included in 167 (73.2%) informative meta-analyses: 1156 (59.1%) were judged as 
low, 475 (24.3%) unclear, and 325 (16.6%) high risk of bias. 
There was a strong association between judgements of low risk of bias for sequence generation and 
allocation concealment (OR 10.4 [95% confidence interval 8.6, 12.5]) (Table 3). Odds ratios for this 
association were consistent across types of outcome variable. Associations between low risk of bias 
judgements for the other 5 pairs of domains were of smaller magnitude, with odds ratios across all 
trials varied between 1.8 and 2.9 (Table 3). 
Table 4 and Web Figure 3 show results from univariable analyses (based on Model A). Intervention 
effect estimates were exaggerated by an average 9% in trials judged as at high or unclear risk of bias 
for sequence generation (ROR 0.91 [95% Cr-I 0.86, 0.98]). There was only a modest increase in 
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0.21]). Mean bias varied between meta-analyses, although this variability was imprecisely estimated 
(SD 0.10 [95% Cr-I 0.02, 0.20], Table 4). There was no convincing evidence that the magnitude of 
average bias differed according to the type of outcome. Meta-analyses with subjective outcomes 
contributed the most data to the analysis, and the average bias among these studies was similar to 
the overall result (ROR 0.90 [95% Cr-I 0.83, 0.98]). In multivariable analyses (based on Model B) the 
association between risk of bias judgement and intervention effect estimate was attenuated after 
adjusting for risk of bias judgements for allocation concealment, blinding and incomplete outcome 
data (ROR 0.95 [95% Cr-I 0.89, 1.03]). The average bias was similar across all outcome types (Table 
5, Web Figure 4). 
As there was a strong association between sequence generation and allocation concealment, the 
estimates of average bias for these two domains may be expected to be similar. Intervention effect 
estimates were exaggerated by an average 8% (ROR 0.92 [95% Cr-I 0.86, 0.98]) in trials judged to be 
at high or unclear risk of bias for allocation concealment, but there was very little evidence of an 
increase in between-trial heterogeneity (SD increase 0.05 [95% Cr-I 0.01, 0.15]). The variability in 
average bias across meta-analyses was small (SD 0.05 [95% Cr-I 0.01, 0.17]). There was little 
evidence that the average bias varied according to type of outcome. Estimates of both between-trial 
and between meta-analysis heterogeneity in bias were low for all outcome types. As for sequence 
generation, the analysis adjusted for the other three domains (Model B) produced an attenuated 
estimate of average bias (ROR 0.96 [95% Cr-I 0.88, 1.03]) and the estimates were very similar across 
all outcome types (Table 5, Web Figure 4). 
Intervention effect estimates were exaggerated by an average 13% (ROR 0.87 [95% Cr-I 0.80, 0.93]) 
in trials judged to be at high or unclear risk of bias for blinding. Between-trial heterogeneity was 
modestly increased for such studies (SD increase 0.10 [95% Cr-I 0.02, 0.25]), and average bias 
varied between meta-analyses (SD 0.12 [95% Cr-I 0.02, 0.24]). There was little evidence that 
intervention effects differed according to type of outcome. Increases in between-trial heterogeneity 
(SD increase 0.22 [95% Cr-I 0.04, 0.36]), and between-meta-analysis heterogeneity in average bias 
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than for all-cause mortality or other objective outcomes. In adjusted analysis (Model B), the estimated 
effect of high or unclear risk of bias due to blinding was similar to the unadjusted estimate (ROR 0.88 
[95% Cr-I 0.81, 0.94]). 
There was little evidence that intervention effects were exaggerated in trials judged to be at high or 
unclear risk of bias for incomplete outcome data (ROR 0.98 [95% Cr-I 0.92, 1.05]). The corresponding 
estimated increase in between-trial heterogeneity was small (SD 0.05 [95% Cr-I 0.01, 0.15]). There 
was little evidence that average bias or increases in between-trial heterogeneity varied according to 
type of outcome. The adjusted estimates were very similar to unadjusted (Table 5, Web Figure 4). 
The results of the sensitivity analysis (Model A) in which trials with an unclear risk of bias judgement 
were combined with those at low risk of bias are shown in Web Table 1. The average intervention 
effects in meta-analyses with high risk of bias for blinding compared with those with low or unclear 
risk of bias were exaggerated on average by 13 % (ROR 0.87 [95% Cr-I 0.79, 0.95]), consistent with 
the main analysis. For the other three bias domains the credible intervals for estimates of average 
bias included the null.  These analyses included fewer informative meta-analyses, especially for 
sequence generation and allocation concealment, and consequently have wider credible intervals. 
Estimated increases in between-trial heterogeneity were larger for sequence generation, compared 
with that observed in the main analysis.  
The separate estimates for subgroups of meta-analyses with „other objective‟ and „semi-objective‟ 
outcomes (which were analysed together in the main analysis) were similar to each other for 
allocation concealment and blinding. They differed somewhat for sequence generation (RORs 0.85 
[95% Cr-I 0.67, 1.09] for other objective and 1.08 [95% Cr-I 0.91, 1.34] for semi-objective outcomes) 
and incomplete outcome data (RORs 0.94 [95% Cr-I 0.72, 1.22] for other objective and 1.11 [95% Cr-I 
0.93, 1.30] for semi-objective), but the credible intervals are wide and overlapping (Web Table 2).  
In multivariable models with interaction terms (Model C), an interaction was observed between 
allocation concealment and blinding (ROR 0.84 [95% Cr-I 0.74, 0.96]), and between sequence 
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blinding may introduce greater bias in estimation of intervention effects within studies with inadequate 
randomization than within studies with adequate randomization.  
 
DISCUSSION 
Using a collection of 2443 trials included in 228 meta-analyses, our estimates of the association 
between average intervention effect estimates and routinely collected risk of bias judgements for 
sequence generation, allocation concealment, blinding and incomplete outcome data confirm that 
problems with randomization and a lack of blinding are on average associated with a modest (around 
10%) exaggeration of treatment effect estimates. Lack of blinding appears to have the largest 
influence on treatment effect estimates: this remains after adjusting for other domains. There was little 
evidence that these biases varied according to the type of outcome measure assessed: although 
there were some differences in RORs for different outcome types in univariable analyses, the credible 
intervals overlapped and the differences were attenuated or disappeared in adjusted analyses. We 
found little evidence that trials assessed as at high risk of bias for incomplete outcome data produced 
systematically different estimates compared with trials at low risk of bias for this domain, for all types 
of outcome measures. Variability of treatment effects was higher in trials that lacked blinding and had 
subjective outcomes, suggesting that for such trials the direction and magnitude of bias is 
unpredictable. Such variability in bias was observed both between trials within a meta-analysis and 
across meta-analyses. There was little evidence of such variation in bias for other bias domains or for 
objectively determined outcomes.  Multivariable analyses suggested that effects of individual risk of 
bias domain judgements were less than additive, in that estimated effects of two bias domain 
judgements together were less than the combined individual effects.  
To our knowledge, this study represents the most comprehensive attempt to date to quantify the 
influence of four bias domains on intervention effect estimates from randomized controlled trials using 
routinely collected risk of bias assessments from published Cochrane reviews. Our findings indicate 
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providing some degree of validation of the risk of bias tool. However, to interpret our findings as 
evidence of bias due to the methods implemented in the trials, it is important to consider the accuracy 
and reliability of these risk of bias assessments. The assessments were made by a large number of 
Cochrane review authors with varying degrees of experience and training, and we did not replicate 
assessments to determine how appropriate they were. Although detailed guidance on how to assess 
risk of bias in trials included in Cochrane reviews is available in chapter 8 of the Cochrane 
Handbook,(18) review authors have reported that they find aspects of the assessment difficult.(22) 
Indeed, some studies have reported that the assessor agreement and inter-rater reliability of the risk 
of bias tool is suboptimal.(23, 24) Specifically, individual reviewers have different criteria for judging a 
study to be „low risk‟ of bias: some may be more confident to make a judgment with less information, 
while others would opt for „unclear risk‟. Standard advice is that two assessors independently assess 
risk of bias and resolve disagreements through discussion. We presume that this advice was 
followed. As a safeguard that recommended assessment methods were followed at least to some 
extent, we restricted eligibility to reviews that had completed all five prescribed bias domains. It is 
possible that individual review teams had their own criteria for rating study „low risk‟ for each of the 
domains, which may have differed from those described in the handbook.  
In our main analyses, risk of bias judgements were dichotomized so that “high” and “unclear” risk 
were considered together. This allows for like-for-like comparisons with results from most of the 
previous empirical studies, including our previous study.(17) Furthermore, there were few “high” risk 
of bias judgements, so analyses with the alternative dichotomization of “high” versus “low” or “unclear” 
risk of bias were not informative. For domains of sequence generation and allocation concealment, a 
“high” risk of bias judgement was recorded in only 3% and 6% trials, respectively (Table 2). We 
demonstrated that Cochrane assessors frequently reach a judgement of “unclear” risk of bias (Table 
2). Inadequate reporting of key features of trial design is a likely explanation of this high rate of 
uncertainty, particularly for methods of sequence generation and allocation concealment. This 
observation is consistent with findings from Turner et al. that allocation concealment was reported in 
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Our adjusted results for sequence generation and allocation concealment are largely consistent with 
recent meta-analyses of all previous meta-epidemiologic studies reported in a recent systematic 
review.(26) Blinding and incomplete data in studies included in this review were not assessed in the 
same way as in our study and cannot be meaningfully compared with our results. Our results for 
average bias are slightly smaller than those from our previous study (the BRANDO study – Bias in 
Randomized and Observational Studies).(17)  This may be dilution due to measurement error, arising 
because the risk of bias assessments in the current study were conducted by a heterogeneous group 
of Cochrane reviewers. In contrast, assessments used in the BRANDO study were done by teams of 
trained methodologists, and data were only combined in the BRANDO analyses where the definitions 
for adequate versus inadequate study method were consistent across studies. Our finding that the 
lack of blinding in trials with subjective outcomes can lead to biased effect estimates, but the direction 
and magnitude of such bias is unpredictable, also confirms a finding from the BRANDO study. The 
main difference between findings from the current study and the BRANDO study is that we do not see 
a clear difference in the magnitude of bias according to type of outcome.   
In summary, our results confirm that some aspects of the conduct of randomized trials, particularly 
blinding, are associated with a modest exaggeration of treatment effects on average, but there is little 
evidence that the average bias differs according to whether the outcome was subjectively or 
objectively assessed. However, lack of blinding in trials with subjective outcomes leads to increased 
heterogeneity and hence unpredictable bias in effect estimates. As far as possible, clinical and policy 
decisions should be cautious when they are based on trials in which blinding was not reported or not 
feasible and outcome measures were subjectively assessed. Future developments of tools for 
assessing risk of bias in randomized trials (27, 28) should reflect this observation and collect 
information on the subjectivity of an outcome. Facilities for capture of detailed routine assessments of 
risk of bias in randomized trials should be made available for future meta-epidemiological research 
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Table 1. Characteristics of Included Meta-analyses and Trials 
Characteristics of meta-analyses and trials Meta-analyses (N=228) Trials (N=2443) 
  n % n % 




    Pregnancy and childbirth (O) 28 12.3 387 15.8 
  Mental & behavioural (F)  27 11.8 286 11.7 
  Circulatory (I)  21  9.2 259 10.6 
  Respiratory (J) 20 8.8 196 8.0 
  Genitourinary (N)  19 8.3 214 8.8 
  Perinatal (P) 18 7.9 155 6.3 
  Digestive (K) 17 7.5 193 7.9 
  Infectious & parasitic (A-B)  11 4.8 113 4.6 
  Neoplasms (C-D)  11 4.8 103 4.2 
  Nervous system (G) 10 4.4 102 4.2 
  Injury & poisoning (S-T)  10 4.4 98 4.0 
  Other ICD-10 chapters 34 14.9 319 13.1 
  Unclassified 2  0.9 18 0.7 
Type of experimental intervention 
  Pharmacological 151 66.2 1688 69.1 
  Provision of care 14 6.1 111 4.5 
  Surgical interventions or procedures 12 5.3 126 5.2 
  Psychosocial & behavioural 11 4.8 125 5.1 
  Other 40 17.5 393 16.1 
Type of comparison intervention 
  Pharmacological 26 11.4 251 10.3 
  Surgical interventions or procedures 8 3.5 99 4.1  
  Other active interventions 4 1.8 33 1.4 
  Placebo / no treatment a 58 25.4 677 27.7 
  Placebo 51 22.4 560 22.9 
  Standard/usual care 32 14.0 307 12.6 
  No treatment 25 11.0 233 9.5 
  Standard care / placebo / no treatment 
a
 24 10.5 283 11.6 
Type of outcome measure 
b
 
  All-cause mortality 42 18.4 429 17.6 
  Other objective 20 8.8 197 8.1 
  Subjective 127 55.7 1356 55.5 
  Mixture of objective and subjective 
a 
2 0.9 70 2.9 
  Semi-objective 37 16.2 391 16.0 
ICD-10 = International Classification of Diseases, 10
th
 edition (World Health Organization).  
a 
Combined at meta-analysis level;  
b
 Other objective: automated or semi-automated laboratory measures including biochemical measurements 
and serological tests; birthweight, live births, preterm birth, clinical pregnancy, un-intended pregnancy, non-
cephalic births; Semi-objective (outcomes for which ascertainment is accurate but their occurrence was 
influenced by a patient‟s or care-provider‟s subjective judgment): blood transfusion given, prescribed anti-
platelet medication, caesarean section, spontaneous vaginal birth, preterm birth, oxytocin augmentation, failure 
of extubation, surgical evacuation, conversion to open surgery, need for further surgery, radical resection, 
hospital admissions, admissions to neonatal intensive care unit, hospital readmissions, presentations at 
emergency department, compliance with intervention, completion of study, withdrawals or dropouts from the 
study, discontinuation of treatment; not remaining in contact with psychiatric services; Subjective: signs and 
symptoms of disease and improvement thereof; symptom scales and scores; mental health outcomes, imaging 
and radiological outcomes, pain, quality of life, adverse events of treatment, other patient reported outcomes or 
those relying on a diagnosis by a physician, cause-specific deaths. Mixture: meta-analyses where some trials 
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Risk of bias domain judgements Low risk High risk Unclear risk 
 n % n % n % 
Sequence generation 1143 46.8 74 3.0 1226 50.2 
Allocation concealment  1033 42.3 143 5.9 1267 51.9 
Blinding  1119 45.8 683 28.0 641 26.2 
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Table 3. Associations Between Risk of Bias Domains 













 OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Sequence generation, Allocation concealment  10.4 8.6, 12.5 11.3 7.1, 17.9 16.7 7.9, 34.9 9.7 6.1, 15.4 9.5 7.4, 12.2 
Sequence generation, Blinding 2.5 2.2, 3.0 3.1 2.1, 4.6 2.0 1.0, 3.8 2.2 1.5, 3.3 2.8 2.2, 3.4 
Sequence generation, Incomplete outcome data 2.1 1.8, 2.4 2.7 1.8, 4.0 5.3 2.8, 9.8 1.7 1.1, 2.6 1.8 1.4, 2.2 
Allocation concealment, Blinding 2.9 2.4, 3.4 4.0 2.7, 6.0 6.0 3.0, 12.1 1.3 0.8, 1.9 3.2 2.6, 4.1 
Allocation concealment, Incomplete outcome data 2.2 1.8, 2.6 2.9 1.9, 4.4 4.4 2.4, 8.3 1.3 0.9, 2.0 2.0 1.6, 2.5 
Blinding, Incomplete outcome data 1.8 1.5, 2.1 1.8 1.2, 2.6 1.4 0.7, 2.6 2.1  1.4, 3.2 1.8 1.5, 2.3 
OR = Odds ratio; CI = confidence interval. 
 
a
 Outcomes for which ascertainment is accurate but their occurrence was influenced by a patient‟s or care-provider‟s subjective judgment (e.g. duration of 
hospital stay, admissions, withdrawals, caesarean section).  
b
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Table 4. Estimated Ratios of Odds Ratios and Between-Meta-Analysis Heterogeneity in Mean Bias Associated With Risk of Bias Judgements, 
According to Type of Outcome Measure: Univariable Analyses (Model A) 
Risk of bias domain and 
outcome 








Meta-analyses Trials ROR 95% Cr-I Kappa 95% Cr-I Phi 95% Cr-I 
Sequence generation: High/unclear risk of bias vs. low risk of bias         
 All 189 2,158 0.91 0.86, 0.98 142 0.09 0.02, 0.21 0.10 0.02, 0.20 
 Mortality 34 363 0.84 0.71, 1.01 27 0.13 0.01, 0.39 0.09 0.01, 0.37 
 Other objective/Semi-objective 47 523 0.99 0.87, 1.16 38 0.10 0.01, 0.31 0.14 0.01, 0.41 
 Subjective/Mixed 108 1,272 0.90 0.83, 0.98 77 0.08 0.01, 0.21 0.08 0.01, 0.22 
Allocation concealment: High/unclear risk of bias vs. low risk of bias      
 All 188 2,121 0.92 0.86, 0.98 139 0.05 0.01, 0.15 0.05 0.01, 0.17 
 Mortality 35 358 0.84 0.71, 1.01 27 0.07 0.01, 0.30 0.12 0.01, 0.42 
 Other objective/ Semi-
objective 
49 524 0.96 0.86, 1.07 40 0.04 0.01, 0.14 0.05 0.01, 0.19 
 Subjective/Mixed 104 1,239 0.91 0.83, 0.99 72 0.08 0.01, 0.25 0.06 0.01, 0.20 
Blinding: High/unclear risk of bias vs. low risk of bias      
 All 144 1,678 0.87 0.80, 0.93 105 0.10 0.02, 0.25 0.12 0.02, 0.24 
 Mortality 31 327 0.83 0.72, 0.97 25 0.06 0.01, 0.26 0.06 0.01, 0.25 
 Other objective/ Semi-
objective 
32 334 0.94 0.81, 1.10 24 0.06 0.01, 0.21 0.06 0.01, 0.28 
 Subjective/Mixed 81 1,017 0.83 0.73, 0.93 56 0.22 0.04, 0.36 0.19 0.03, 0.34 
Incomplete outcome data: High/unclear risk of bias vs. low risk of bias      
 All 167 1,956 0.98 0.92, 1.05 112 0.05 0.01, 0.16 0.05 0.01, 0.15 
 Mortality 29 303 0.92 0.79, 1.08 19 0.08 0.01, 0.32 0.06 0.01, 0.24 
 Other objective/ Semi-
objective 
43 471 1.03 0.90, 1.19 28 0.07 0.01, 0.25 0.06 0.01, 0.25 
 Subjective/Mixed 95 1,182 0.97 0.88, 1.07 65 0.06 0.01, 0.17 0.10 0.01, 0.30 
ROR = ratio of odds ratios; Cr-I = credible interval; Kappa - measure of within meta-analysis heterogeneity; Phi - measure of between meta-analysis 
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Table 5. Estimated Ratios of Odds Ratios and Between-Meta-Analysis Heterogeneity in Mean Bias Associated Risk of Bias Judgements, 
According to Type of Outcome Measure: Multivariable Analyses (Model B) 
Risk of bias domain and 
outcome 










Trials ROR 95% Cr-I Kappa 95% Cr-I Phi 95% Cr-I 
Sequence generation: High/unclear risk of bias vs. low risk of bias         
 All 189  2,158 0.95 0.88, 1.03 142 0.08 0.02, 0.18 0.11 0.03, 0.22 
 Mortality 34  363 0.92 0.75, 1.18 27 0.14 0.02, 0.36 0.14 0.03, 0.42 
 Other objective/Semi-objective 47 523 1.06 0.90, 1.28 38 0.14 0.03, 0.33 0.20 0.04, 0.44 
 Subjective/Mixed 108  1,272 0.94 0.84, 1.04 77 0.08 0.02, 0.18 0.11 0.02, 0.24 
Allocation concealment: High/unclear risk of bias vs. low risk of bias      
 All 188 2,121 0.96 0.88, 1.03 139 0.06 0.01, 0.15 0.07 0.02, 0.16 
 Mortality 35 358 0.92 0.74, 1.13 27 0.11 0.03, 0.29 0.15 0.03, 0.42 
 Other objective/ Semi-
objective 
49 524 0.94 0.81, 1.08 40 0.07 0.01, 0.18 0.09 0.02, 0.25 
 Subjective/Mixed 104 1,239 0.95 0.86, 1.07 72 0.10 0.02, 0.23 0.08 0.02, 0.20 
Blinding: High/unclear risk of bias vs. low risk of bias      
 All 144 1,678 0.88 0.81, 0.94 105 0.10 0.02, 0.22 0.12 0.03, 0.23 
 Mortality 31 327 0.87 0.73, 1.03 25 0.10 0.02, 0.26 0.10 0.02, 0.28 
 Other objective/ Semi-
objective 
32 334 0.95 0.79, 1.12 24 0.09 0.02, 0.24 0.10 0.02, 0.34 
 Subjective/Mixed 81 1017 0.84 0.75, 0.95 56 0.17 0.04, 0.33 0.19 0.05, 0.35 
Incomplete outcome data: High/unclear risk of bias vs. low risk of bias      
 All 167 1,956 1.01 0.94, 1.09 112 0.07 0.01, 0.16 0.07 0.02, 0.16 
 Mortality 29 303 0.99 0.82, 1.18 19 0.11 0.02, 0.31 0.10 0.02, 0.30 
 Other objective/ Semi-
objective 
43 471 1.04 0.90, 1.21 28 0.11 0.02, 0.30 0.09 0.02, 0.26 
 Subjective/Mixed 95 1,182 1.00 0.90, 1.12 65 0.07 0.01, 0.17 0.11 0.03, 0.27 
Analyses for each bias domain were adjusted for risk of bias judgements for the other three domains (Model B in Web Appendix 2). For graphical 
representation of these results, see Web Figure 4. ROR = ratio of odds ratios; Cr-I = credible interval; Kappa - measure of within meta-analysis heterogeneity; 
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 Figure 
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Meta-Analyses Removed (n = 18,521) 
Meta-analyses with <5 trials (n = 17,056) 
No events in both trial arms (n = 43) 
No summary estimate for meta-analysis (n = 12) 
Nonbinary data (n = 738) 
Unclear which intervention was experimental (n = 589) 
Included in the BRANDO Study (n = 83)
 
Meta-Analyses Removed That Overlapped With “Selected” Meta-
Analyses (n = 1,562) 
Included Data 
Systematic reviews (n = 211) 
Meta-analyses (n = 228) 
Trials (n = 2,428) 
Trial results (n = 2,443) 
Trial Results Removed From Included Meta-Analyses (n = 361) 
Control group of multi-arm repeated (n = 2) 
Nonrandomized study (n = 3) 
Result already included within another review (n = 12) 
Result repeated across subgroups within meta-analysis (n = 52) 
Cross-over trials (same patients in both groups) (n = 2) 
Results with no events in either intervention arm (n = 290) 
Meta-Analyses Removed That Overlapped With Another Meta-
Analysis From Another Review (n = 8) 
 
Supplied Data 
 Systematic reviews (n = 1,399) 
 Meta-analyses (n = 29,659) 
Data Remaining 
Systematic reviews (n = 242) 
Meta-analyses “selected” (n = 264) 
Data Remaining 
 Systematic reviews (n = 815) 
 Meta-analyses (n = 20,347) 
Data Remaining 
Systematic reviews (n = 242)  
Meta-analyses (n = 1,826) 
Data Remaining 
Systematic reviews (n = 239) 
Meta-analyses (n = 256) 
Meta-Analysis Subgroups Removed Because Only Subgroup-Level 
Summary Estimates Were Provided (1 Subgroup Kept per Meta-
Analysis) (n = 769) 
 
Trials With 2 Results Each Within a Meta-Analysis Were Kept 
When There Was No Patient Overlap Between Them (n = 15) 
 
Meta-Analyses With <5 Trials Removed Because of the Above 
Trial Exclusions (n = 28), Resulting in Exclusion of 82 Further Trial 
Results and 28 Reviews 
 
Systematic Reviews Removed Because Not All 5 Risk-of-Bias 
Domains Were Activated (n = 584) 
Systematic Reviews Removed Because of the Above Removal of 
Meta-Analyses (n = 573) 
Systematic Reviews Removed Because of the Above Removal of 
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